Victor Priego, MD
Medical Oncology · Bethesda, MDNPI 1003875295
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $30,019 of the $41,577 with a category attached, or 72.2%. It is spread thinly across 60 manufacturers, the largest accounting for just 15.7%. Reporting peaked in 2019 at $11,134 and has fallen 57.2% since, to $4,769 in 2025.
Across 1,334 payments — averaging $31.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$7K
- Bristol Myers Squibb$4K
- Jazz Pharmaceuticals Inc.$3K
- Johnson & Johnson$2K
- AstraZeneca$2K
- Pfizer$1K
- plus $21K from 54 others
Across 318 payments — averaging $6376.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pharmaessentia USA Corporation$540K
- Pfizer$358K
- Bayer$225K
- Takeda Pharmaceuticals U.S.A., Inc.$159K
- Astrazeneca UK Limited$102K
- Incyte Corporation$87K
- plus $555K from 15 others
What the payments were for
- Consulting fees$10,59525%
- Travel & lodging$3281%
- Food & beverage$30,01972%
- Education$6352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,577 in reported general payments places this provider in the 75th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 39 | $671,868 |
| JakafiRuxolitinib Phosphate | 32 | $549,896 |
| IbrancePalbociclib | 24 | $360,127 |
| FotivdaTivozanib Hcl | 11 | $316,819 |
| DopteletAvatrombopag Maleate | 11 | $263,906 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 27 | $228,313 |
| PromactaEltrombopag Olamine | 14 | $174,735 |
| LenvimaLenvatinib Mesylate | 19 | $169,803 |
| CalquenceAcalabrutinib Maleate | 12 | $161,255 |
| AdakveoCrizanlizumab-Tmca | 12 | $118,339 |
| XareltoRivaroxaban | 91 | $102,028 |
| EliquisApixaban | 97 | $99,948 |
| KyprolisCarfilzomib | 12 | $49,853 |
| Letrozole | 49 | $1,656 |
| Tamoxifen Citrate | 15 | $723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $3,765 | $671,86839 claims |
| Incyte CorporationJakafi | $761 | $549,89632 claims |
| PfizerIbrance, Eliquis | $1,443 | $460,074121 claims |
| NovartisPromacta, Adakveo | $6,513 | $293,07426 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $774 | $228,31327 claims |
| Eisai Inc.Lenvima | $773 | $169,80319 claims |
| AstraZenecaCalquence | $1,661 | $161,25512 claims |
| Johnson & JohnsonXarelto | $2,234 | $102,02891 claims |
| AmgenKyprolis | $757 | $49,85312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 180 medical oncology providers in Maryland.
Other medical oncology in Bethesda
- Adrian SenderowiczBethesda$1.6M
- Lee HelmanBethesda$43K
- Christopher KlebanoffBethesda$26K
- Christian HinrichsBethesda$17K
- Mario EisenbergerBaltimore$2.9M
- Mohit NarangOwing Mills$1.3M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.